TrialPhase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
Trial details
- Registry ID
- NCT04224272
- Phase
- Phase 2
Drug research
ZW25 (Zanidatamab)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as JZP598; ZIIHERA®; ZW25; Zanidatamab
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantNCT04224272 | Jazz Pharmaceuticals | Phase 2 | Completed | 2023-04-28Actual |
| A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract CancersNCT04466891 | Jazz Pharmaceuticals | Phase 2 | Completed | 2023-07-28Actual |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerNCT03929666 | Jazz Pharmaceuticals | Phase 2 | Completed | 2025-08-30Actual |
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Trial details
- Registry ID
- NCT04466891
- Phase
- Phase 2
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Trial details
- Registry ID
- NCT03929666
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |